CRISPR Therapeutics Stock News

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

CRISPR and Vertex recently earned approval for a gene-editing treatment, Casgevy. Casgevy shows the potential of CRISPR's platform and should improve its financial results.

These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.

In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels wit

Does CRISPR Therapeutics AG (CRSP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline tar

Amazon has plenty of room to grow despite its already huge size. CRISPR Therapeutics is at a pivotal point, with U.S. approvals for its lead candidate potentially on the way.

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for i

CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD,

There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies a

Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare ge

Cathie Wood is as bullish as ever, but recent economic indicators point to strength for her favorite stocks. In an interview, Cathie Wood emphasized that deflation is now a key concern rather than inf

CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.

Shares of Crispr Therapeutics CRSP, +1.68% and Vertex Pharmaceuticals Inc. VRTX, -5.57% gained ground premarket on Thursday after the companies got the world's first regulatory authorization for a med